Lilly and Novo look set for a battle in glucose-sensitive insulin, and other areas too.
Device deal making is back in a big way, despite the munificence of venture funds.
Spacs still have their supporters, but SEC scrutiny and mixed post-deal performance mean that the story is losing its lustre.
And four other potential targets that could make sense for the beleaguered group.
If the first quarter was quiet for takeovers the second saw M&A grind to a halt. What can the matter be?
And Royalty Pharma has paid a king’s ransom.